GENinCode (LON:GENI) Shares Up 6% – Should You Buy?

GENinCode Plc (LON:GENI)’s stock price was up 6% during trading on Friday . The company traded as high as GBX 1.25 and last traded at GBX 1.01. Approximately 24,361,582 shares were traded during mid-day trading, an increase of 354% from the average session volume of 5,363,759 shares. The stock had previously closed at GBX 0.95.

GENinCode Stock Up 6.0%

The firm has a market capitalization of £7.58 million, a P/E ratio of -0.48 and a beta of 0.56. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The stock has a 50 day moving average of GBX 0.86 and a 200-day moving average of GBX 1.02.

GENinCode (LON:GENI) last posted its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The business had revenue of GBX 308 million during the quarter. Research analysts predict that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.